P. Pandey

DNA Repair Pathways as Determinants of PARP Inhibitor Resistance and Therapeutic Targets in Cancer

Poly (ADP-ribose) polymerase inhibitors (PARPi) have transformed the treatment landscape for homologous recombination-deficient (HRD) cancers, particularly those harboring BRCA1/2 mutations, including breast, ovarian, prostate, and pancreatic cancers, by exploiting the synthetic lethality induced by HR deficiency (HRD)...

Localized immunotherapy via dissolving microneedles for the prevention of breast cancer recurrence.

Electrospun silk sericin-poly(lactic acid) coaxial nanofiber scaffold for esmolol and ferulic acid co-delivery in expedited diabetic wound healing.

Diabetic foot ulcers (DFUs) are chronic, infection-prone wounds that heal poorly due to impaired angiogenesis, persistent inflammation, and elevated oxidative stress, creating a substantial clinical and economic burden and highlighting the need for advanced extracellular matrix-mimicking dressings. Therefore, we have d...

Epigenetic Reprogramming in Cancer Metastasis: From Histone Modifications to Therapeutic Vulnerabilities

Current insights into the epigenetic regulation of cancer metastasis are summarized, emerging epigenetic therapies are evaluated, and translational opportunities to advance precision anti-metastatic strategies and improve patient outcomes are highlighted.